Bliss Biopharmaceutical
Hangzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An oncology-focused biotech developing next-generation antibody-drug conjugates and bispecific antibodies.
Oncology
Technology Platform
Proprietary platforms for generating optimized antibody-drug conjugates (ADCs) with novel linkers/payloads and engineered bispecific antibodies.
Opportunities
The global ADC market is expanding rapidly, offering significant potential for novel agents with better therapeutic windows.
Risk Factors
High clinical development risk and potential for severe toxicity could derail programs in a highly competitive field.
Competitive Landscape
Faces intense competition from global ADC leaders like AstraZeneca/Daiichi Sankyo and numerous Chinese biotechs, requiring superior clinical data for differentiation.